Form Type:  8-K
Filing Date:  5/20/2014 
CIK:  0001010086 
Address:  660 MADISON AVENUE
SUITE 1700
City, State, Zip:  NEW YORK, New York 10065 
Telephone:  212-672-9100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.045 (6.38%)  
Trade Time: 
May 27  
Market Cap: 
Trade SIGA now with 

© 2016  
Description of Business
Since we were incorporated in Delaware on December 28, 1995, SIGA has pursued the research, development and commercialization of novel products for the prevention and treatment of serious infectious diseases, including products for use in defense against biological warfare agents such as smallpox and Arenaviruses. Our lead product, ST-246®, is an orally administered antiviral drug that targets orthopox viruses. In December 2006 the FDA granted Orphan Drug designation to ST-246® for the prevention and treatment of smallpox. In May 2009, we submitted a response to a Request for Proposal ("RFP") issued by BARDA with respect to the purchase of 1.7 million courses of a smallpox antiviral (the "BARDA Smallpox RFP"), and, in June 2009, BARDA informed us that our response to the BARDA Smallpox RFP was deemed technically acceptable and in the competitive range. There can be no assurance that SIGA or any other company will receive an award pursuant to this RFP.
Register and access this filing in:     
  FORM 8-K
      Item 5.07. Submission of Matters to a Vote of Security Holders.